Monitoring Requirements for Telehealth Ketamine: What Good Programs Require

Monitoring requirements for telehealth ketamine exist because no clinician is physically present when a patient takes the medication at home. That absence of in-room supervision is the biggest safety tradeoff of at-home ketamine compared to in-person IV infusion in a clinic. Responsible telehealth programs cannot eliminate that gap, but they can narrow it with structured monitoring before, during, and after each session, plus ongoing clinical oversight for patients who continue treatment for months at a time. This guide describes what that monitoring looks like in practice, and what to ask a platform if the details are not published on its site.

Pre-Session Monitoring

Vital Sign Assessment

Before every session, patients at responsible telehealth programs record their blood pressure (systolic and diastolic), resting heart rate, and oxygen saturation using a pulse oximeter, then report these numbers to the provider or log them in the platform. Documenting vitals before each session creates a longitudinal record. A trend, such as blood pressure that creeps upward across several sessions, can flag emerging cardiovascular risk before it becomes a serious problem.

Symptom Check-In and PDMP Verification

Most programs also require a short pre-session questionnaire covering current mood, any unusual symptoms, use of medications, alcohol, or other substances in the past 24 hours, and whether a sitter is present. Behind the scenes, the prescribing provider should check the state Prescription Drug Monitoring Program, a state-run database that tracks controlled substance prescriptions, to confirm the patient is not receiving overlapping prescriptions elsewhere. According to the PDMP Training and Technical Assistance Center, PDMP review is a standard part of responsible controlled substance prescribing, not an optional step. Ketamine prescribing for at-home use also operates within a specific federal and state regulatory framework; see our telehealth ketamine legality overview for how that framework shapes what a provider can and must do.

During-Session Monitoring

Live Video and Sitter Presence

Some platforms keep a live video connection open throughout the session, with a provider or care guide checking in periodically. This is the highest standard of during-session monitoring in the at-home model and comes closest to having a clinician in the room. It is not universal. Some platforms make live monitoring optional or rely on phone availability instead. Ask directly: is someone watching a live video feed during my session, or are they simply reachable by phone?

Most responsible programs also require a sober adult sitter to be physically present, particularly for the first several sessions. The sitter is not a trained clinician. Their role is to provide a grounding presence, watch for obvious signs of distress, and call for help if something goes wrong. Sitter requirements vary by platform: some require a sitter for every session, others require one only for the first one to three sessions, and some only strongly recommend a sitter rather than require one.

Emergency Contact Verification and Mid-Session Vitals

Before each session, the provider should confirm the patient has emergency contact information on hand: the provider's emergency line, the sitter's phone, and 911. Some programs also ask patients or their sitter to take a blood pressure reading mid-session, near the peak of the medication's effects. This is harder to do while impaired, but it provides data on how the patient's vitals are behaving at the point of greatest physiological stress.

Post-Session Monitoring

Same-Day Check-In and Vitals

A post-session check-in, ideally within about two hours of the session ending, is standard at responsible programs. It can take the form of a scheduled video call with a care guide, a secure message exchange, or a brief in-app questionnaire. The check-in confirms the patient has returned to baseline, that no adverse events occurred, and that the patient is safe to be without supervision. Post-session blood pressure and heart rate readings add data on how quickly cardiovascular effects resolve.

Symptom and Integration Tracking

Beyond acute safety checks, most programs administer standardized outcome measures such as the PHQ-9 for depression or GAD-7 for anxiety at regular intervals. This data helps a provider assess whether treatment is working, identify patients who are not responding and may need a different approach, and detect early signs of adverse psychological effects such as increased anxiety, destabilization, or cognitive changes.

Long-Term Monitoring

Responsible programs schedule regular clinical appointments, typically monthly or quarterly, for a comprehensive symptom reassessment with validated scales, a review of blood pressure trend data, a self-report on cognitive function such as memory and concentration, and a re-evaluation of whether continued treatment is still clinically justified.

Liver and Urinary Tract Monitoring

Patients on ongoing maintenance dosing, generally more than three to four months of continuous use, should have periodic liver function tests. The exact schedule varies by provider and patient risk factors, but quarterly or biannual testing is a reasonable standard for ongoing maintenance. Long-term ketamine use has also been associated with urinary tract problems in some patients, including urgency, frequency, and pain on urination. Providers should ask about these symptoms at every follow-up, and any patient who develops them should be evaluated promptly.

What to Ask When Evaluating a Platform

A platform that can answer these questions clearly and specifically has thought seriously about monitoring. One that is vague, inconsistent, or unable to answer is likely offering less oversight than the standard of care calls for. Our platform comparison tool and provider directory are useful starting points for checking how different programs describe their monitoring practices before you enroll.

References

• StatPearls: Ketamine, a clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary, an NCBI chemical database entry with molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine, National Library of Medicine consumer drug information on uses, administration, and precautions
• U.S. Department of Health and Human Services: Telehealth, a guide to telehealth services, regulations, and patient resources
• SAMHSA: National Helpline, a free treatment referral and information service